The FDA has approved Merck's once-daily cholesterol pill Lipfendra (enlicitide), marking the first oral PCSK9 inhibitor.

Merck's new cholesterol therapy, Lipfendra, has received FDA approval in the United States. The once-daily oral PCSK9 inhibitor is described as 'game-changing,' shown to reduce LDL cholesterol by approximately 56% to 60% when combined with statins.

The U.S. Food and Drug Administration (FDA) has approved Lipfendra, a novel pill designed to help manage cholesterol levels.

Drugmaker Merck has announced that its new cholesterol-fighting drug, Lipfendra, has received FDA approval. The medication can be used in conjunction with or as an alternative to statins.